The US Food and Drug Administration expanded approval of Pfizer's Talzenna plus Xtandi combination on October 26 to men with HRR-mutated metastatic prostate cancer that has not yet become resistant to hormone therapy, based on a 52% reduction in progression or death in the TALAPRO-3 trial.
The US Food and Drug Administration expanded approval of talazoparib, sold as Talzenna, plus enzalutamide, sold as Xtandi, on October 26, Pfizer announced. The combination now covers men with metastatic prostate cancer that is androgen pathway modulation-naive or -sensitive and carries homologous recombination repair, or HRR, gene mutations detected by an FDA-authorized test.
The approval moves the combination into an earlier treatment setting. Talzenna plus Xtandi was first cleared in June 2023 for metastatic castration-resistant prostate cancer with HRR mutations, a stage that follows resistance to hormone therapy. The new label reaches patients before that resistance develops, with eligibility tied to genetic testing across 12 HRR genes, including BRCA and non-BRCA variants.
The evidence comes from the phase 3 TALAPRO-3 trial, which enrolled 599 patients and compared talazoparib plus enzalutamide against placebo plus enzalutamide. Adding talazoparib cut the risk of radiographic progression or death by 52%, a hazard ratio of 0.48 with a 95% confidence interval of 0.36 to 0.65. Median radiographic progression-free survival was not reached in the talazoparib arm, against 45.8 months in the control arm, and an estimated 77% of patients remained progression-free at three years.
The results were presented at the 2026 American Society of Clinical Oncology annual meeting and published in the New England Journal of Medicine, and the application received FDA Priority Review under Project Orbis, with reviews ongoing in Australia and Canada. Overall survival data remained immature at the time of the progression-free survival analysis, and the FDA announcement reports no survival estimates, a limitation the coverage states plainly.
Safety is part of the picture. Grade 3 or higher anemia occurred in 51% of patients receiving Talzenna plus Xtandi, against 3% in the control group, according to Pfizer. Companion diagnostics FoundationOne CDx and FoundationOne Liquid CDx were cleared alongside the approval to identify patients with qualifying alterations.
The approval follows a setback last year, when an FDA advisory committee voted unanimously against expanding the combination to patients regardless of HRR mutation status. Analysts cited in the coverage expect the earlier-line expansion to have a negligible impact on Pfizer's bottom line, with Talzenna bringing in $107 million in the first half of 2026, but the decision matters more for patients: it makes a targeted option available at a stage where it may delay progression longer.